A B S T R A C T We have previously reported that virulent egg yolk-grown Legionella pneumophila, Philadelphia 1 strain, multiplies intracellularly in human blood monocytes and only intracellularly under tissue culture conditions. In this paper, we have investigated the effect of erythromycin and rifampin on L. pneumophila-monocyte interaction in vitro; erythromycin and rifampin are currently the drugs of choice for the treatment of Legionnaires' disease.
Inhibition of L. pneumophila multiplication in monocytes by antibiotics is reversible; when the antibiotics are removed from infected monocyte cultures after 2 d, L. pneumophila resumes multiplication.
This study indicates that patients with Legionnaires' disease under treatment with erythromycin and rifampin require host defenses to eliminate L. pneumophila, and that inadequate host defenses may result in relapse after cessation of therapy.
I NTRODUCTION
We have previously reported that Legionella pneumophila, the agent of Legionnaires' disease, is a facultative intracellular pathogen. The bacteria multiply intracellularly in human monocytes and alveolar macrophages, and, under tissue culture conditions, multiplication is exclusively intracellular (1, 2) . Virulent in vivo grown L. pneumophila is completely resistant to the bactericidal effects of human serum, even in the presence of high titer anti-L. pneumophila antibody (3) . The bacteria also resist killing by human polymorphonuclear leukocytes (PMN) even in the presence of specific antibody and complement (3, 4) . Antibody and complement promote the binding of L. pneumophila to monocytes, but do not inhibit the rate of bacterial multiplication in monocytes (4) . In vitro ac-tivated human monocytes and alveolar macrophages do inhibit the intracellular multiplication of L. pneumophila (2, 5) .
Erythromycin and rifampin are currently the drugs of choice for the treatment of Legionnaires' disease. Both clinical experience and in vivo studies indicate that these antibiotics are efficacious in treating Legionnaires' disease (6) (7) (8) (9) . L. pneumophila grown under cell-free conditions on artificial media is inhibited from multiplying by these antibiotics and is killed by concentrations of these antibiotics that are the same or somewhat higher than the minimal inhibitory concentration (MIC)' (10, 11) .
In this study, we have examined the effect of erythromycin and rifampin on L. pneumophila located intracellularly in human monocytes. We shall demonstrate (a) that these antibiotics rapidly inhibit the intracellular multiplication of L. pneumophila at concentrations comparable to those that inhibit L. pneumophila multiplication under cell-free conditions in artificial medium; (b) that L. pneumophila multiplying in human monocytes is resistant to killing by concentrations of erythromycin and rifampin that are bactericidal to L. pneumophila multiplying extracellularly in artificial medium; (c) that L. pneumophila multiplying in human monocytes is resistant to killing by erythromycin and rifampin even at concentrations of these antibiotics comparable to or higher than peak blood levels in humans; and (d) that L. pneumophila inhibited from multiplying in monocytes by erythromycin and rifampin retains its capacity to multiply in monocytes after the antibiotics are removed from the medium.
METHODS
Media. Egg yolk buffer (EYB), with (EYB-BSA) or without 1% bovine serum albumin, and RPMI 1640 medium were prepared or obtained as described previously (1) . Buffered yeast extract (BYE) broth, pH 6.9, was prepared with 5 g/ liter bovine serum albumin fraction V (Reheis Co., Inc., Armour Pharmaceutical Co., Phoenix, AZ), 10 in methanol, diluted in water to 1,000 Ag activity/ml, and stored in small aliquots in vials at -70'C. On the day of the experiments the frozen preparation was thawed and diluted to the desired concentration in RPMI 1640 medium. Rifampin (Rimactane diagnostic powder, Ciba Pharmaceutical Company, Summit, NJ), 1,014 ug activity/mg was stored under vacuum at 40C. On the day of the experiment, the powder was dissolved in methanol and diluted to the desired concentration first in water and then in RPMI 1640 medium.
In this paper, the concentrations of antibiotics are stated in micrograms per milliliter, but refer to micrograms of antibiotic activity per milliliter.
Agar. Modified charcoal yeast extract agar was prepared in 100X15-mm petri dishes (1).
Serum. Venous blood was obtained, clotted, and serum separated and stored at -70'C until use (13) . Normal (nonimmune) human serum (type AB) with an indirect fluorescent antibody anti-L. pneumophila titer (14) Table II ). The other monocytes were incubated for 24 h with 1.25 or 12.5 ug/ml erythromycin or 0.01-100 Mg/ml rifampin and then lysed by sonication. The bacteria in all cultures were pelleted by centrifugation two times at 12,000 g (to wash away antibiotic from cultures treated with them), resuspended in 2 ml RPMI 1640 medium, and CFU of L. pneumophila per milliliter determined. Centrifugation resulted in a loss of 0.24 and 0.17 logs in experiments 1 and 2, respectively, Table II .
Assay for determining bactericidal effect of various concentrations of antibiotic on L. pneumophila multiplying extracellularly in broth. For comparison with the above assay, concentrations of antibiotic tested against L. pneumophila multiplying intracellularly in that assay were tested against L. pneumophila multiplying extracellularly in BYE broth. Midlogarithmic phase broth-grown L. pneumophila were prepared and added to plastic tubes containing BYE broth and antibiotic as in the "Assay for determining the MIC and MBC of erythromycin and rifampin for L. pneumophila multiplying extracellularly" except the final concentrations of antibiotic were 1.25 and 12.5 ;g/ml erythromycin and 0.01, 0.02, 0.1, and 1.0 jg/ml rifampin. As a control for bacterial survival in a medium that does not support bacterial multiplication, L. pneumophila were added to plastic tubes containing EYB-BSA. Triplicate tubes were prepared for each concentration of bacteria and antibiotic. All tubes were sealed, rotated continuously at 37°C for 24 h, and CFU per milliliter determined after serial dilution as in the "Assay for determining the MIC and MBC of erythromycin and rifampin for L. pneumophila multiplying extracellularly." In the experiment shown in Table III , CFU per milliliter of L. pneumophila in control tubes containing EYB-BSA decreased 0.4 log for inoculum A and 1.1 log for inoculum B.
Sonication of infected monocyte cultures. Monocytes were lysed by sonication with a 2.54-cm Diam high-gain disrupter horn attached to a sonicator (Heat Systems Ultrasonics, Inc., Plainview, NY). Sonication was performed under sterile conditions for 10 s continuously with the output control of the sonicator set at the 4 position. This amount of sonic energy lysed the leukocytes completely but did not reduce bacterial CFU (1).
RESULTS
MIC and MBC of erythromycin and rifampin multiplying extracellularly. We determined the MIC and MBC of erythromycin and rifampin for the L. pneumophila strain used in this paper (Philadelphia 1 strain) on bacteria multiplying extracellularly in BYE broth (Methods). The mean MIC for three experiments, each with two concentrations of bacteria, were 0.375 ,g/ml erythromycin and 0.002 Ag/ml rifampin (Table I ). The mean MBC for two experiments, each with two concentrations of bacteria, were 1 Ag/ml erythromycin and 0.009 Ag/ml rifampin, higher than the MIC (Table I) . CFU per milliliter were reduced 23 logs at the MBC, but cultures were not sterilized (Table I) .
Erythromycin and rifampin inhibit the intracellular multiplication of L. pneumophila in human monocytes. We infected mononuclear cell cultures with L. pneumophila in the presence of 0-1.25 ,ug/ml erythromycin or 0-0.01 ,ug/ml rifampin and assayed the culture medium daily for CFU of L. pneumophila (Methods). L. pneumophila multiplied several logs in the presence of 0-0.125 Mg/ml erythromycin but multiplication was completely inhibited by 1.25 ,ug/ml erythromycin (Fig. 1A) . The MIC of erythromycin for L. pneumophila multiplying in broth was in this range (Table I) .
L. pneumophila multiplied several logs in the presence of 0 or 0.001 Ag/ml of rifampin, but multiplication was completely inhibited by 0.01 ,g/ml rifampin ( Fig. 2A) . The MIC of rifampin for L. pneumophila multiplying in broth was also in this range (Table I) .
Erythromycin (1.25 Mg/ml) and rifampin (0.01 ,g/ ml) inhibited L. pneumophila multiplication whether added to mononuclear cells immediately before or (Fig. 3A) or rifampin (Fig. 3B) (Fig. 4) . Control cultures were incubated either with or without antibiotic throughout the course of the experiment, i.e., before and after the cultures were washed. In cultures incubated with inhibitory concentrations of erythromycin or rifampin, L. pneumophila multiplication was inhibited as in previous experiments (Fig. 4) . When these antibiotics were removed from the cultures, L. pneumophila multiplied several logs (Fig. 4) Days after infection Hours ofter antibiotics odded FIGURE 5 Erythromycin and rifampin inhibit the intracellular multiplication of L. pneumophila in monocytes within 1 h of addition to midlogarithmic phase bacteria. Monocyte monolayers in plastic petri dishes containing 2 ml RPMI 1640 medium and 15% fresh human serum were infected with L. pneumophila, incubated until the bacteria were in the midlogarithmic phase of growth, and vigorously washed to remove extracellular bacteria (Methods). The cultures were then incubated for 0, 1, 4, or 8 h with erythromycin (1.25 g/iml), rifampin (0.01 ,ug/ml), or no antibiotic, as indicated.
At the end of the incubation, the monocytes were lysed by sonication and CFU of L. pneumophila in the medium were determined. Each point represents the mean for three replicate cultures±SE.
ml were bacteriostatic but not bactericidal for L. pneumophila multiplying intracellularly in monocytes, these concentrations of antibiotic were bactericidal for L. pneumophila multiplying under cell-free conditions in broth. Therefore, we investigated whether higher concentrations of antibiotics, equal to or greater than peak serum concentrations in humans, are bactericidal for L. pneumophila located intracellularly in monocytes.
To examine this issue, we infected monocyte monolayers with L. pneumophila and allowed the bacteria to multiply to midlogarithmic phase. We then washed replicate cultures of monocytes to remove extracellular bacteria, and incubated the cultures for 24 h in the presence of 1.25 or 12.5 ,ug/ml of erythromycin or 0.01-100 ,ug/ml of rifampin. The peak serum concentration of intravenously administered erythromycin is -10 ,g/ml (17) and the peak serum concentration of orally administered rifampin is -8 Ag/ml (18) . We omitted antibiotics from control cultures but lysed them by sonication to prevent further growth of L. pneumophila during the 24-h incubation. After 24 h, we lysed the monocyte cultures treated with antibiotics, washed the bacteria free of antibiotics by highspeed centrifugation, and assayed for CFU of L. pneumophila (Methods).
In erythromycin-treated cultures, CFU were slightly decreased (0.22-0.36 logs) in comparison with controls (Table 1I ), but there was no significant difference in CFU between cultures treated with 1.25 ,ug/ml, 1.25 times the MBC for extracellularly multiplying L. pneumophila and cultures treated with 12.5 iug/ml, 10 times that concentration and a concentration comparable to peak serum levels.
In cultures treated with 0.01 Ag/ml of rifampin, approximately the MBC for extracellularly multiplying L. pneumophila, CFU were only slightly decreased (0.05 or 0.24 logs) below the control level (Table II) . In cultures treated with higher concentrations of rifampin, CFU were decreased in a dose-response fashion. However, even at a concentration of 100 ug/ml, 10 times the peak serum level, and 10,000 times the MBC for extracellularly multiplying L. pneumophila, CFU were reduced by only 1.3-1.7 logs. A control experiment showed that CFU of L. pneumophila were not decreased as a result of exposure of bacteria to high concentrations of rifampin after lysis of the monocytes or as a result of carry-over of rifampin with the bacteria through the centrifugation steps. Bacteria from cultures that had been sonicated and incubated for 24 h without antibiotics were divided into two groups and 100 tig/ml rifampin added to one of the two groups before the centrifugation steps. After centrifugation, there was no difference in the number of CFU of L. pneumophila in the two groups.
Thus, L. pneumophila resists killing by erythromycin and rifampin even when these antibiotics are at concentrations equal to or greater than peak serum concentrations in humans.
By way of comparison, we studied the effect of concentrations of antibiotics used in the studies presented in Table I1 on Monocyte monolayers were prepared in 35-mm petri dishes, infected with L. pneumophila, and the bacteria allowed to multiply until they were in the logarithmic phase of growth (Methods). The monolayers were then washed to remove extracellular bacteria. Control monolayers were lysed by sonication to prevent further growth of L. pneumophila and incubated for 24 h without antibiotics. The other monolayers were incubated for 24 h with erythromycin (1.25 or 12.5 jug/ml) or rifampin (0.01-100 ug/ml) and then lysed by sonication. The bacteria in all cultures were washed by highspeed centrifugation to remove antibiotics from those cultures that had been treated with them, and CFU in each culture were determined as described in Methods. Each point represents the mean for three replicate monocyte cultures±SE. Expt., experiment.
Mean MBC, as determined in Table I (1 ug/ml erythromycin and 0.009 Mg/ml rifampin).
I (Log CFU in antibiotic-treated cultures) -(log CFU in control cultures not treated with antibiotics). (Table II) , L. pneumophila multiplying extracellularly under cell-free conditions were highly susceptible to killing by erythromycin and rifampin (Table III) ; CFU per milliliter were reduced 1.7-3.6 logs below control levels in erythromycin-treated cultures, and 3.9-5 or more logs below control levels in rifampin-treated cultures.
DISCUSSION
We found that L. pneumophila multiplying intracellularly in human monocytes is inhibited from multiplying by concentrations of erythromycin and rifampin comparable to those that inhibit L. pneumophila multiplying extracellularly in artificial medium. However, L. pneumophila multiplying extracellularly is killed by relatively low concentrations of these antibiotics; the MBC are only three-to fivefold higher then the MIC. In contrast, L. pneumophila multiplying intracellularly is highly resistant to killing by erythromycin and rifampin even at concentrations comparable to or higher than peak blood levels in humans, levels 12 times the MBC for erythromycin and 10,000 times the MBC for rifampin.
Several differences between intracellular and extracellular bacteria may account for the disparity in their susceptibility to antibiotics. Bacteria multiplying extracellularly are directly exposed to antibiotics and under standardized physiologic conditions i.e., pH, osmolality, nutrient concentrations, et cetera, set by the investigator. Bacteria multiplying intracellularly are very differently situated; for an antibiotic to be effective against them, the antibiotic must first enter the host cell and gain access to the compartment in which they reside. Even then, whether or not the antibiotic can exert its characteristic antimicrobial effect is critically dependent upon the physiologic characteristics (e.g., the pH) of the pathogen's environment, which in turn are dependent upon other aspects of the host-parasite relationship such as whether the pathogen inhibits phagosome-lysosome fusion; L. pneumophila inhibits phagosome-lysosome fusion (19) .
In addition to differences in location and environment, bacteria multiplying intracellularly may differ from bacteria multiplying extracellularly in their intrinsic susceptibility to antibiotics, since these bacteria differ from each other in other fundamental ways. For example, L. pneumophila growing extracellularly in artificial medium differ morphologically from bacteria growing intracellularly; in contrast to intracellularly growing bacteria, the extracellularly growing bacteria tend to form filaments and chains (20) . Also, extracellularly grown bacteria have been found to be less virulent for guinea pigs and chicken embryos than intracellularly grown bacteria (21) .
In vivo studies of antibiotic efficacy against L. pneumophila have also yielded results at variance with those obtained from studies involving L. pneumophila multiplying on artificial medium. Several antibiotics active against L. pneumophila growing on artificial medium have been found to lack efficacy against L. pneumophila in vivo (8) (9) (10) (11) . It is noteworthy that one such antibiotic, penicillin G, was reported by Johnson et al. (22) to be taken up very poorly by rabbit alveolar macrophages; in contrast, erythromycin and rifampin, which are active against L. pneumophila both in vivo and under cell-free conditions, were taken up readily by rabbit alveolar macrophages (8) (9) (10) (11) 22) . In fact, erythromycin and rifampin were among the few antibiotics tested that were concentrated in rabbit alveolar macrophages-erythromycin 20-fold and rifampin twofold (22) . Thus, at least in the case of these three antibiotics to which L. pneumophila grown on artificial medium is sensitive, there is a good correlation between uptake by rabbit alveolar macrophages in vitro and efficacy in vivo.
Our earlier work indicates that in vivo, L. pneumophila multiplies only intracellularly (1) . If so, then the present study indicates that in vivo L. pneumophila is resistant to killing by erythromycin and rifampin since both intracellularly multiplying bacteria and extracellular bacteria that are not multiplying are resistant to killing by these antibiotics. Since L. pneumophila probably multiplies only intracellularly in vivo, we suspect that the studies reported here of intracellularly multiplying L. pneumophila more likely reflect the in vivo situation than studies involving L. pneumophila multiplying extracellularly on artificial medium.
Our data show that L. pneumophila inhibited by erythromycin and rifampin retains its capacity to multiply in monocytes after the antibiotics are removed. This suggests that, in vivo, host defenses may be necessary to eliminate L. pneumophila bacteria from patients on antibiotics. Host defenses may also be required to inhibit multiplication of bacteria that survive a course of treatment. Previous work from this laboratory indicates that cell-mediated immunity plays a critical role in limiting the multiplication of L. pneumophila (5, 23) . Viewed in this way, the role of antibiotics in Legionnaires' disease may be to suppress L. pneumophila multiplication long enough for the
